Friday, 26 January

08.30 - 08.40 Welcome
M. Brausi, Modena (IT)

08.40 - 09.00 Opening address
The future of urology: The EAU perspective
F. Debruyne, Arnhem (NL)

09.00 - 13.10 Prostate Cancer I: Diagnosis, pathology, screening, active surveillance
Chairs: M. Brausi, Modena (IT) F. Debruyne, Arnhem (NL)

09.00 - 09.15 Reflex testing with serum, urine and tissue biomarkers: Which, when and how viable?
B. Djavan, Vienna (AT)

09.15 - 09.20 Questions

09.20 - 09.35 Genetic testing in inherited prostate cancer
A. Alcaraz, Barcelona (ES)

09.35 - 09.40 Questions

09.40 - 09.55 Morphologic basis of mpMRI prostate cancer evaluation
F. Algaba, Barcelona (ES)

09.55 - 11.30 MRI imaging targeted prostate biopsy: Comparing 3 different techniques. Is there really a difference in results?

11.00 - 11.15 Biopsy or monitoring patients with negative MRI
J. Hugosson, Gothenburg (SE)

11.15 - 11.30 Discussion

11.30 - 12.00 Break
Friday, 26 January

12.00 - 12.15  How have recommendations against prostate cancer screening impacted the incidence and mortality of prostate cancer in the US  
C. Evans, Sacramento (US)

12.15 - 12.25  Discussion

12.25 - 13.10  ROUND TABLE: Treatment modalities for intermediate risk prostate cancer: surgery vs hypofractionation RT vs focal therapy vs active surveillance  
Chairs:  J. Hugosson, Gothenburg (SE)  
A. Villers, Lille (FR)

12.25 - 12.33  Surgery  
S. Joniau, Leuven (BE)

12.33 - 12.41  Hypofractionation RT  
C. Cozzarini, Milan (IT)

12.41 - 12.49  Focal therapy  
A. Villers, Lille (FR)

12.49 - 12.57  Active surveillance  
M. Roobol, Rotterdam (NL)

12.57 - 13.10  Discussion

13.10 - 14.00  Lunch

14.00 - 14.10  Renal cancer I: Localised: Alternative approaches for characterisation of renal tumours  
Chairs:  P. Chlost, Cracow (PL)  
A. Volpe, Novara (IT)

14.00 - 14.10  MRI  
J. Walz, Marseilles (FR)

14.10 - 14.20  Conventional and optical renal mass biopsy  
T. De Reijke, Amsterdam (NL)

14.20 - 14.30  Liquid biopsy  
M. von Brandenstein, Cologne (DE)

14.30 - 14.45  Discussion

14.45 - 15.00  The WHO ISUP classification of renal tumours: What has changed?  
G. Martignoni, Verona (IT)

15.00 - 15.05  Discussion

15.05 - 15.30  Treatment of renal cancer in the elderly (>75 years)  
Chairs:  A. Minervini, Florence (IT)  
H. Van Poppel, Leuven (BE)

15.05 - 15.30  Is partial nephrectomy always the best choice for T1b tumours?  
Yes  
G. Janetschek, Salzburg (AT)

15.15 - 15.25  No  
M. Kuczyk, Hanover (DE)

15.25 - 15.30  Discussion
Friday, 26 January

15.30 - 16.00  DEBATE: Clamped vs. unclamped partial nephrectomy (open, lap. robotic)

15.30 - 15.40  Clamped
P. Chlosta, Cracow (PL)

15.40 - 15.50  Unclamped
M. Gallucci, Rome (IT)

15.50 - 16.00  Discussion

16.00 - 16.30  Panel discussion of clinical cases: Localised RCC
Chair: P. Mulders, Nijmegen (NL)
Panelists: A. Breda, Barcelona (ES)
G. Stewart, Cambridge (GB)
H. Van Poppel, Leuven (BE)
J. Walz, Marseilles (FR)

16.30 - 16.45  Surveillance after nephrectomy: On the way towards evidence based protocols
A. Bex, Amsterdam (NL)

16.45 - 17.15  Break

17.15 - 18.50  Controversial subjects on bladder cancer
The role of extended lymphadenectomy for bladder cancer
Chairs: G. Thalmann, Berne (CH)
E. Xylinas, Paris (FR)

17.15 - 17.25  The American perspective
C. Evans, Sacramento (US)

17.25 - 17.35  European perspective
R. Hautmann, Neu-Ulm (DE)

17.35 - 17.45  Discussion

17.45 - 18.10  Robotic assisted radical cystectomy: Always the right urinary diversion?
17.45 - 17.55  No
G. Thalmann, Berne (CH)

17.55 - 18.05  Yes
H. Van Der Poel, Amsterdam (NL)

18.05 - 18.10  Discussion

18.10 - 18.50  Is there a role for local treatment in metastatic disease?
18.10 - 18.20  The urologist perspective
A. Stenzl, Tubingen (DE)

18.20 - 18.30  The medical oncologist perspective
A. Necchi, Milan (IT)

18.30 - 18.40  Discussion
Saturday, 27 January

08.30 – 11.30  Prostate cancer II: Locally advanced  Location: Plenary Room
Chairs: A. Alcaraz, Barcelona (ES)
S. Joniau, Leuven (BE)

08.30 – 08.45  Tools for detection of node metastasis: PSMA guided surgery
T. Maurer, Munich (DE)

08.45 – 09.40  Management of loco-regional recurrence after definitive treatment

08.45 – 09.00  Cryoablation
B. Malavaud, Toulouse (FR)

09.00 – 09.15  Salvage radiation therapy
A. Bossi, Villejuif (FR)

09.15 - 09.30  Salvage radical prostatectomy – Robotic
H. Van Der Poel, Amsterdam (NL)

09.30 - 09.40  Discussion

09.40 – 10.20  DEBATE: Reappraisal of neoadjuvant therapy for high and very high-risk PCA
09.40 – 09.55  Yes - it does make sense
A. Volpe, Novara (IT)
09.55 - 10.10  No - it is useless
N. Mottet, Saint Etienne (FR)

10.10 - 10.20  Discussion

10.20 – 11.00  Is lymph node dissection necessary in prostate cancer?

10.20 - 10.35  The American view
C. Evans, Sacramento (US)
10.35 - 10.50  The European view
M. Graefen, Hamburg (DE)

10.50 - 11.00  Discussion

11.00 - 11.30  Break

11.30 – 12.20  Penile cancer
Reducing treatment aggressiveness without impairing outcomes
Chairs: B. Ayres, London (GB)
D. Pfister, Cologne (DE)

11.30 - 11.40  Conservative surgery for penile cancer: Indications and techniques
S. Minhas, London (GB)

11.40 - 11.45  Discussion
Saturday, 27 January

11.45 – 11.55  From radical inguinal lymph node dissection to sentinel lymph node dissection for penile cancer  
               B. Ayres, London (GB)

11.55 – 12.00  Discussion

12.00 – 12.10  Evolution of surgical techniques in testis cancer  
               D. Pfister, Cologne (DE)

12.10 – 12.20  Discussion

12.20 – 14.10  Urothelial cancer II: Non muscle invasive bladder cancer  
               Chairs:  J. Catto, Sheffield (GB)  
                       J. Palou, Barcelona (ES)

12.20 – 12.30  New techniques for bladder tumour resection: Are they better than conventional TURBT?  
               U. Nagele, Hall (AT)

12.30 – 12.35  Discussion

12.35 – 12.45  Complications of TURBT  
               A. Masson-Lecomte, Creteil (FR)

12.45 – 12.50  Discussion

12.50 – 13.00  Socio-economic impact of BCG shortage  
               M. Colombel, Lyon (FR)

13.00 – 13.05  Discussion

13.05 – 13.15  Genomic classification of non muscle invasive bladder tumours  
               J. Catto, Sheffield (GB)

13.15 – 13.20  Discussion

13.20 – 13.30  New diagnostic tools for upper urinary tract TCC  
               A. Breda, Barcelona (ES)

13.30 – 13.35  Discussion

13.35 – 14.10  Panel discussion – Second opinion in difficult clinical cases  
               Chair:  M. Babjuk, Prague (CZ)  
               Panelists:  J. Catto, Sheffield (GB)  
                           M. Colombel, Lyon (FR)  
                           J. Palou, Barcelona (ES)  
                           E. Xylinas, Paris (FR)
Sunday, 28 January

09.00 - 10.30  
Prostate cancer III: Advanced and metastatic disease  
Location: Plenary Room

Chairs:  
G. Janetschek, Salzburg (AT)  
H. Van Der Poel, Amsterdam (NL)

09.00 - 09.15  
Open vs robotic surgery for locally advanced prostate cancer: Oncological and functional outcomes  
P. Gontero, Turin (IT)

09.15 - 09.20  
Discussion

09.20 - 10.00  
New trends for treatment of oligo metastatic prostate cancer

09.20 - 09.30  
Radical prostatectomy  
M. Brausi, Modena (IT)

09.30 - 09.40  
Radiotherapy  
B. Jereczek-Fossa, Milan (IT)

09.40 - 09.50  
Chemo-hormone therapy  
N. Mottet, Saint Etienne (FR)

09.50 - 10.00  
Discussion

10.00 - 10.30  
Salvage LND after radical prostatectomy for PSA recurrence: An up-date

10.00 - 10.10  
Robotic (Video)  
N. Suardi, Milan (IT)

10.10 - 10.20  
Open (Video)  
S. Joniau, Leuven (BE)

10.20 - 10.30  
Discussion

10.30 - 11.00  
Break

11.00 - 12.00  
The best of uro-oncology in 2017  
Location: Plenary Room

Chairs:  
A. Breda, Barcelona (ES)  
M. Sedelaar, Nijmegen (NL)

11.00 - 11.15  
Prostate cancer  
P. Ghadjar, Berlin (DE)

11.15 - 11.30  
Renal cancer  
E. Linares Espinos, Madrid (ES)

11.30 - 11.45  
Urothelial cancer  
A. Noon, Sheffield (GB)

11.45 - 12.00  
Testis and penile cancer  
M. Salagierski, Zielona Gora (PL)
# Sunday, 28 January

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12.00 - 13.30</strong></td>
<td>Renal cancer II: Locally advanced and metastatic</td>
<td>S. Brookman May, Munich (DE) O. Rodríguez Faba, Barcelona (ES)</td>
</tr>
<tr>
<td><strong>12.00 - 12.15</strong></td>
<td>The role of neoadjuvant and adjuvant therapy in kidney cancer</td>
<td>A. Bamias, Athens (GR)</td>
</tr>
<tr>
<td><strong>12.15 - 12.20</strong></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>12.20 - 12.35</strong></td>
<td>Cytoreductive nephrectomy for metastatic RCC in the targeted therapy era</td>
<td>V. Matveev, Moscow (RU)</td>
</tr>
<tr>
<td><strong>12.35 - 12.40</strong></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>12.40 - 12.55</strong></td>
<td>The revival of immunotherapy in RCC and novel clinical trials</td>
<td>A. Necchi, Milan (IT)</td>
</tr>
<tr>
<td><strong>12.55 - 13.00</strong></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>13.00 - 13.30</strong></td>
<td>Clinical case discussion</td>
<td>A. Bamias, Athens (GR) E. Linares Espinos, Madrid (ES) V. Matveev, Moscow (RU) A. Necchi, Milan (IT) O. Rodríguez Faba, Barcelona (ES)</td>
</tr>
<tr>
<td><strong>13.30 - 13.35</strong></td>
<td>Closing remarks</td>
<td>M. Brausi, Modena (IT)</td>
</tr>
</tbody>
</table>
### ESU/ESUI Hands-on Training in prostate MRI reading for urologists

**Date:** 27 January 2018  
**Time:** 14.30 - 18.00  
**Room:** Hamburg, Passenger Terminal  
**Chair:** V. Kasivisvanathan, London (GB)  
**Faculty:**  
- J. Barentsz, Nijmegen (NL)  
- V. Kasivisvanathan, London (GB)  
- V. Panebianco, Rome (IT)  
- F. Sanguedolce, Barcelona (ES)

14.30 - 14.40  
The importance of prostate MRI to the urologist: Overview of the course  
V. Kasivisvanathan, London (GB)

14.40 - 15.10  
Introduction to MRI sequences, scoring systems, PI-RADS  
J. Barentsz, Nijmegen (NL)

15.10 - 15.35  
Interactive case discussion – reporting MRI using PI-RADS  
V. Panebianco, Rome (IT)

15.35 - 15.45  
Treatment implications of an mpMRI-driven diagnostic pathway  
F. Sanguedolce, Barcelona (ES)

15.45 - 15.50  
Introduction to the MIM software for MRI interpretation  
V. Kasivisvanathan, London (GB)

15.50 - 16.35  
Assessment: Hands - on baseline assessment of MRI interpretation  
Supervised by Faculty

16.35 - 16.50  
Review of assessment scans  
J. Barentsz, Nijmegen (NL)

16.50 - 17.35  
Assessment: Hands - on baseline assessment of MRI interpretation  
Supervised by Faculty

17.35 - 17.50  
Review of assessment scans  
V. Panebianco, Rome (IT)

17.50 - 18.00  
Close

**Registration fee:** € 40 (excluding VAT)  
**Limited places available – For further information please go to the registration desk.**
ESOU18  
15th Meeting of the EAU Section of Oncological Urology  
26-28 January 2018, Amsterdam, The Netherlands  
www.esou18.org  

ESU course on Kidney Cancer

Date  27 January 2018  
Time  14.30 – 17.30  
Room  Matterhorn, Movenpick Hotel  
Chair  J. Walz, Marseille (FR)  

14.30 – 14.35  
European School of Urology: A unique possibility for urological education  
J. Walz, Marseille (FR)  

14.35 – 14.40  
Introduction and aims  
J. Walz, Marseille (FR)  

14.40 – 15.00  
Diagnosis, biopsy and staging of kidney cancer  
J. Walz, Marseille (FR)  

15.00 – 15.15  
Management and treatment of kidney cancer  

15.00 – 15.15  
How to plan a surgical procedure and how to estimate surgical risk  
Speaker: B. Challacombe, London (GB)  

15.15 – 15.25  
Videos on how I do it:  

15.15 – 15.25  
Radical nephrectomy  
A. Bex, Amsterdam (NL)  

15.25 – 15.35  
Partial nephrectomy  
B. Challacombe, London (GB)  

15.35 – 15.45  
Focal therapy  
J. Walz, Marseille (FR)  

15.45 – 15.55  
Active surveillance  
A. Minervini, Florence (IT)  

15.55 – 16.05  
Discussion  

16.05 – 16.20  
Break  

16.20 – 16.50  
Round table on how to avoid and manage complications  
Bleeding, Prolonged ischemia, Decreased renal function, Urinary and vascular fistulae  
Panel: A. Bex, Amsterdam (NL)  
B. Challacombe, London (GB)  
A. Minervini, Florence (IT)  
J. Walz, Marseille (FR)  

16.50 – 17.05  
Factors influencing functional and oncological outcome of kidney cancer treatment  
A. Minervini, Florence (IT)  

17.05 – 17.25  
Medical treatment of kidney cancer:  
“neoadjuvant” treatment of localized and advanced disease, Adjuvant treatment of kidney cancer, Treatment of metastatic disease  
A. Bex, Amsterdam (NL)  

17.25 – 17.30  
Discussion and close  

This course is available free to all delegates: No registration necessary.